Abstract:Objective: To evaluate the efficacy and safety of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of patients with recurrent ovarian cancer after previous treatment with platinum and taxane agents. Patients and Methods: A total of 42 patients with recurrent ovarian cancer who had an evaluable lesion and provided informed consent for participation in the present study were analyzed. Irinotecan was administered intravenously at a dose of 60 mg/m2 on days 1 and 15. Etoposide was administered orally at a daily dose of 50 mg/body weight from days 1 to 21. A 28-day period comprised one cycle. The tumor response, adverse events, progression-free survival, and overall survival were examined. Tumor response was evaluated based on the Response Evaluation Criteria in Solid Tumors and the serum CA125 levels (Gynecologic Cancer Intergroup criteria). Adverse events were assessed according to the NCI-CTCAE (version 3.0). Results: Partial response was observed in 21 patients, stable disease in 14 patients, and progressive disease in 7 patients. The response rate was 50.0%, and the clinical benefit (partial response + stable disease) rate was 83.3%. Hematological toxicities of at least grade 3 severity included leukopenia in 21 patients (50.0%), neutropenia in 22 patients (52.4%), thrombocytopenia in 1 patient (2.4%), anemia in 9 patients (21.4%), and febrile neutropenia in 3 patients (7.1%). Nonhematological toxicities of at least grade 3 severity included queasy feeling in 5 patients (11.9%), vomiting in 3 patients (7.1%), and diarrhea in 2 patients (4.8%). Acute myeloid leukemia occurred in one patient (2.4%). Conclusions: It is suggested that combination chemotherapy with irinotecan plus oral etoposide offers significant clinical benefit to patients with recurrent ovarian cancer previously treated with platinum and taxane agents.

The exploration of the micro-mechanism of the electrophoretic deposition of chitosan

Adsorption of chitosan onto carbonaceous surfaces and its application: atomic force microscopy study.

Preparation of Chitosan Bicomponent Nanofibers Filled with Hydroxyapatite Nanoparticles Via Electrospinning

MOEMS 3D microstructure preparation method based on novel localized electrochemical deposition

Chitosan Hydrogel Structure Modulated by Metal Ions.

Electrophoretic Deposition and Characterization of Curcumin/Chitosan Coatings

Preparation and characteristics of the sulfonated chitosan derivatives electrodeposited onto 316l stainless steel surface

Combination of Micelle Collapse and CuNi Surface Dissolution for Electrodeposition of Magnetic Freestanding Chitosan Film

Control of the Colloidal and Adsorption Behaviors of Chitin Nanocrystals and an Oppositely Charged Surfactant at Solid, Liquid, and Gas Interfaces

Schizophrenic autism. 1. Historical evolution and perspectives.

Tailoring the adhesion of electrophoretic chitosan/bioactive glass coatings by the combined surface pre-treatments of Ti substrates

Electrophoretic Deposition of Graphene Oxide Reinforced Chitosan–hydroxyapatite Nanocomposite Coatings on Ti Substrate

The Preparation And Characterization Of Chitosan Rods Modified With Fe3+ By A Chelation Mechanism

Surgery for Bell's palsy.

Preparation and Characterization of Magnetic Chitosan Microcapsules

Electrophoretic deposition of chitosan–bioglass®–hydroxyapatite–halloysite nanotube composite coating

The electrochemical and in-vitro study on electrophoretic deposition of chitosan/gelatin/hydroxyapatite coating on 316L stainless steel

Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study)

Fabrication of Chitosan Single-Component Microcapsules with a Micrometer-Thick and Layered Wall Structure by Stepwise Core-Mediated Precipitation.

In Situ Mineralization of Hydroxyapatite on Electrospun Chitosan-Based Nanofibrous Scaffolds

Synthesis and characterization of methacrylated chitosan